Get started
Author

Shirley X. Liao

Observed names: Liao, Shirley, Shirley Liao
ORCID: 0000-0002-6529-720X
Observed ORCID: 0000-0002-6529-720X
OpenAlex ID: A5072777076
Major depressive disorder prevalence and risk factors among Syrian asylum seekers in Greece
2018 · Danielle N. Poole, Bethany Hedt-Gauthier, et al. · BMC Public Health · 100
PDF
Uncertainty in the design stage of two‐stage Bayesian propensity score analysis
2020 · Shirley X. Liao, Corwin M. Zigler · Statistics in Medicine · 24
No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score–matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP)
2021 · Helmut Butzkueven, Ludwig Kappos, et al. · Therapeutic Advances in Neurological Disorders · 22
PDF
No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: Real-world evidence from MS PATHS
2022 · Lana Zhovtis Ryerson, Robert T. Naismith, et al. · Multiple Sclerosis and Related Disorders · 21
PDF
Sequential screening for depression in humanitarian emergencies: a validation study of the Patient Health Questionnaire among Syrian refugees
2020 · Danielle N. Poole, Shirley Liao, et al. · Annals of General Psychiatry · 18
PDF
Relationship between medication adherence for opioid use disorder and health care costs and health care events in a claims dataset
2023 · Shirley Liao, Steve Jang, et al. · Journal of Substance Use and Addiction Treatment · 17
Characterizing the ‘feel-good experience’ in Multiple Sclerosis Patients Treated With Natalizumab Or Other Therapies
2022 · John Foley, Regina Berkovich, et al. · Neurodegenerative Disease Management · 7
PDF
Magnetic Resonance Imaging (MRI) Metrics in Routine Clinical Practice: Proof of Concept in MS PATHS (Multiple Sclerosis Partners Advancing Technology for Health Solutions) (1356)
2020 · Elizabeth Fisher, Tobias Kober, et al. · Neurology · 6
Real-World Practice Effects and Effect Modifiers of Neuroperformance Tests in Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) (4135)
2021 · Shirley Liao, Carl de Moor, et al. · Neurology · 3
Implementation of a sequential screening process for depression in humanitarian crises: a validation study of the Patient Health Questionnaire in Syrian refugees
2019 · Danielle Poole, Shirley Liao, et al. · The Lancet Global Health · 2
PDF
Conversion to Non-Active Secondary Progressive Multiple Sclerosis (SPMS) in Patients Who Discontinued or Remained on Natalizumab in the Real-World TYSABRI Observational Program (TOP) (2505)
2021 · Ludwig Kappos, Helmut Butkueven, et al. · Neurology · 1
No difference in radiologic outcomes for natalizumab patients on extended interval dosing compared with standard interval dosing in MS PATHS (1964)
2021 · Lana Zhovtis Ryerson, Robert T. Naismith, et al. · Neurology · 1
Bayesian Causal Inference for Estimating Impacts of Air Pollution Exposure
2019 · Shirley Liao · Digital Access to Scholarship at Harvard (DASH) (Harvard University) · 1
PDF
Longitudinal Analyses of Patient-Reported Outcomes Measurement Information System Pain Scores in the Project Baseline Health Study
2024 · Shirley Liao, Rebecca Fillipo, et al. · Journal of Pain
PDF
119 Long-term effectiveness of natalizumab for RRMS: UK and global interim results from TYSABRI observational program
2022 · Richard Nicholas, Timothy Harrower, et al. · Journal of Neurology Neurosurgery & Psychiatry
Characteristics and clinical outcomes of underserved minority patients with multiple sclerosis treated with peginterferon beta-1a or intramuscular interferon beta-1a in MS PATHS (2392)
2021 · Carrie M. Hersh, Kathryn Fitzgerald, et al. · Neurology
Amélioration ou maintien du statut en matière d’emploi chez les patients atteints de sclérose en plaques rémittente-récurrente (SEP RR) traités par natalizumab dans le cadre l’étude observationnelle TYSABRI TOP
2021 · Gisela Kobelt, Maria Trojano, et al. · Revue Neurologique
Cognitive Impairment and MRI-based Disease Progression in MS PATHS: Variable Susceptibility Across the Lifespan (1334)
2020 · Leigh Charvet, Carl de Moor, et al. · Neurology
Posterior predictive treatment assignment methods for causal inference in the context of time-varying treatments
2020 · Shirley X. Liao, Lucas Henneman, et al. · Epidemiologic Methods
PDF
Works count: 21
Citation count: 223
H-index: 7
I10-index: 6
Year
Topic
Type